EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis

Khai Li Chai iD, Jonathan Wong iD, Robert Weinkove iD, Anastazia Keegan, Philip Crispin, Simon Stanworth iD, C Orla Morrissey, Erica M Wood iD, Zoe K McQuilten iD

Blood Advances · 10.01.2023 · 7 (1) · 20-31

DOI: 10.1182/bloodadvances.2022008073 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Blood Advances, erschienen am 10.01.2023. Verfasst von Khai Li Chai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Common Variable Immunodeficiency, Hematologic Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired hypogammaglobulinemia is common in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM). No previous systematic reviews (SRs) have compared different approaches to infection prevention. We sought to assess the efficacy and safety of prophylactic immunoglobulin, antibiotics, and vaccination in these patients. We performed an SR and meta-analysis of randomized controlled trials (RCTs) evaluating the efficacy and safety of prophylactic immunoglobulin, antibiotics, and vaccination in adult patients with hematological malignancies commonly associated with acquired hypogammaglobulinemia, specifically, CLL, NHL, and MM. We searched PubMed (MEDLINE), EMBASE, and Cochrane Registry up to 9 January 2021. Results for dichotomous data were expressed as relative risk (RR) with 95% confidence interval (CI) and pooled in a random-effects model. This review was registered with PROSPERO CRD42017070825. From 10 576 studies screened, there were 21 completed RCTs and 1 ongoing. Of these, 8 evaluated prophylactic immunoglobulin (n = 370; 7 published before 2000), 5 evaluated prophylactic antibiotics (n = 1587), 7 evaluated vaccination (n = 3996), and 1 compared immunoglobulin to antibiotics (n = 60). Prophylactic immunoglobulin reduced the risk of clinically documented infection (CDI) by 28% (n = 2 trials; RR, 0.72; 95% CI, 0.54-0.96), and vaccination reduced the risk by 63% (RR, 0.37; 95% CI, 0.30-0.45). Prophylactic antibiotics did not reduce the risk. No intervention reduced all-cause mortality. Prophylactic immunoglobulin and antibiotics increased the risk of adverse events. Findings should be interpreted with caution, given the high risk of bias in many studies. There is a clear need for high-quality contemporary trials to establish the effectiveness of different approaches to preventing infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellCommon Variable ImmunodeficiencyHematologic NeoplasmsAdultHumansAnti-Bacterial AgentsRisk

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Department of Hematology, Monash Health, Clayton, VIC, Australia.
  • Department of Hematology, Wellington Blood and Cancer Centre at Capital and Coast District Health Board.
  • Cancer Immunotherapy Programme at Malaghan Institute of Medical Research.
  • Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand.
  • Department of Hematology, King Edward Memorial Hospital, Subiaco, WA, Australia.

ORCID-Profile: Khai Li Chai, Jonathan Wong, Robert Weinkove, Simon Stanworth, Erica M Wood, Zoe K McQuilten

Zitieren

APA

Chai, K. L., Wong, J., Weinkove, R., Keegan, A., Crispin, P., Stanworth, S., Morrissey, C. O., Wood, E. M., & McQuilten, Z. K. (2023). Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis. Blood Advances, 7(1), 20-31. https://doi.org/10.1182/bloodadvances.2022008073

Vancouver

Chai KL, Wong J, Weinkove R, Keegan A, Crispin P, Stanworth S, et al. Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis. Blood Advances. 2023;7(1):20-31. doi:10.1182/bloodadvances.2022008073

BibTeX
@article{Chai2023,
  author = {Chai, Khai Li and Wong, Jonathan and Weinkove, Robert and Keegan, Anastazia and Crispin, Philip and Stanworth, Simon and Morrissey, C Orla and Wood, Erica M and McQuilten, Zoe K},
  title = {Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis},
  journal = {Blood Advances},
  year = {2023},
  volume = {7},
  number = {1},
  pages = {20--31},
  doi = {10.1182/bloodadvances.2022008073}
}
Kostenlos starten →